Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 22.56 -1.40% -0.32
DCPH closed down 1.4 percent on Wednesday, April 25, 2018, on 60 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical DCPH trend table...

Date Alert Name Type % Chg
Apr 25 MACD Bearish Centerline Cross Bearish 0.00%
Apr 25 Outside Day Range Expansion 0.00%
Apr 25 Wide Bands Range Expansion 0.00%
Apr 25 Down 3 Days in a Row Weakness 0.00%
Apr 25 Oversold Stochastic Weakness 0.00%
Apr 24 Wide Bands Range Expansion -1.40%
Apr 23 50 DMA Resistance Bearish -2.51%
Apr 23 MACD Bearish Signal Line Cross Bearish -2.51%
Apr 23 180 Bearish Setup Bearish Swing Setup -2.51%
Apr 23 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.51%

Older signals for DCPH ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
Is DCPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 29.98
52 Week Low 15.15
Average Volume 132,011
200-Day Moving Average 0.0
50-Day Moving Average 24.3912
20-Day Moving Average 23.5845
10-Day Moving Average 24.104
Average True Range 1.7585
ADX 20.54
+DI 13.28
-DI 20.55
Chandelier Exit (Long, 3 ATRs ) 22.5545
Chandelier Exit (Short, 3 ATRs ) 24.4655
Upper Bollinger Band 27.78
Lower Bollinger Band 19.389
Percent B (%b) 0.38
BandWidth 35.578452
MACD Line -0.0777
MACD Signal Line 0.0819
MACD Histogram -0.1596
Fundamentals Value
Market Cap 720.23 Million
Num Shares 31.9 Million
EPS -16.03
Price-to-Earnings (P/E) Ratio -1.41
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.27
Resistance 3 (R3) 25.45 24.73 24.82
Resistance 2 (R2) 24.73 24.04 24.64 24.67
Resistance 1 (R1) 23.65 23.62 23.29 23.46 24.52
Pivot Point 22.93 22.93 22.75 22.84 22.93
Support 1 (S1) 21.84 22.24 21.48 21.66 20.60
Support 2 (S2) 21.12 21.81 21.03 20.45
Support 3 (S3) 20.04 21.12 20.30
Support 4 (S4) 19.85